drugset / Trial / NCT07050368
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
RandomizedParallel-groupSingle-blindTreatment
Summary
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple doses of MLS101 in healthy participants.
Timeline
- Start
- 2025-07-28
- Primary completion
- 2026-01-13
- Completion
- 2026-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Psilocybin | Other / unclassified | — | — |
Indications
No indication recorded.